Shots:
- The company has reported the expansion of its P-III REVERSE-IT study for bentracimab in Canada where the first patients from major health centers globally have been enrolled (approx. 200 patients) and dosed
- Bentracimab demonstrated sustained reversal of the antiplatelet activity of Brilinta (ticagrelor). In a translational study, bentracimab achieved equivalent reversal of branded ticagrelor and multiple ticagrelor generics
- The P-III REVERSE-IT (Rapid and SustainEd ReVERSal of TicagrElor – Intervention Trial) is designed to study the reversal of the antiplatelet effects of ticagrelor with bentracimab in patients with uncontrolled major or life-threatening bleeding or who require urgent surgery/ invasive procedure
Click here to read full press release/ article | Ref: Business Wire | Image: Business Wire
The post PhaseBio Reports First Patients Dosing in its P-III REVERSE-IT Study of Bentracimab in Canada first appeared on PharmaShots.
